Cargando…

Propensity score‐adjusted three‐component mixture model for drug‐drug interaction data mining in FDA Adverse Event Reporting System

With increasing trend of polypharmacy, drug‐drug interaction (DDI)‐induced adverse drug events (ADEs) are considered as a major challenge for clinical practice. As premarketing clinical trials usually have stringent inclusion/exclusion criteria, limited comedication data capture and often times smal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xueying, Li, Lang, Wang, Lei, Feng, Weixing, Zhang, Pengyue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2019
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292662/ https://www.ncbi.nlm.nih.gov/pubmed/31880829 http://dx.doi.org/10.1002/sim.8457

Ejemplares similares

Three‐Component Mixture Model‐Based Adverse Drug Event Signal Detection for the Adverse Event Reporting System
por: Zhang, Pengyue, et al.
Publicado: (2018)

Efficiently mining Adverse Event Reporting System for multiple drug interactions
por: Xiang, Yang, et al.
Publicado: (2014)

Adverse drug events in the prevention and treatment of COVID-19: A data mining study on the FDA adverse event reporting system
por: Guo, Qiang, et al.
Publicado: (2022)

Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database
por: Sonawane, Kalyani B., et al.
Publicado: (2018)

Data Mining of the Public Version of the FDA Adverse Event Reporting System
por: Sakaeda, Toshiyuki, et al.
Publicado: (2013)

Mining FDA drug labels for medical conditions
por: Li, Qi, et al.
Publicado: (2013)

Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions
por: Li, Ying, et al.
Publicado: (2020)

Detecting drug-drug interactions between therapies for COVID-19 and concomitant medications through the FDA adverse event reporting system
por: Jeong, Eugene, et al.
Publicado: (2022)

Statin-Associated Muscular and Renal Adverse Events: Data Mining of the Public Version of the FDA Adverse Event Reporting System
por: Sakaeda, Toshiyuki, et al.
Publicado: (2011)

Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system
por: Huang, Jing, et al.
Publicado: (2020)

Adverse Drug Events by Sex After Adjusting for Baseline Rates of Drug Use
por: Rushovich, Tamara, et al.
Publicado: (2023)

Immunotherapy-related adverse events (irAEs): extraction from FDA drug labels and comparative analysis
por: Wang, QuanQiu, et al.
Publicado: (2018)

Proarrhythmia associated with antiarrhythmic drugs: a comprehensive disproportionality analysis of the FDA adverse event reporting system
por: Wang, Feifei, et al.
Publicado: (2023)

Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: A real-world analysis using the FDA adverse event reporting system
por: Jiao, Xue-Feng, et al.
Publicado: (2023)

Lung Cancer Adverse Events Reports for Angiotensin-Converting Enzyme Inhibitors: Data Mining of the FDA Adverse Event Reporting System Database
por: Meng, Long, et al.
Publicado: (2021)

Proton Pump Inhibitors and the Risk for Fracture at Specific Sites: Data Mining of the FDA Adverse Event Reporting System
por: Wang, Liwei, et al.
Publicado: (2017)

Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review
por: Macklis, Paul C., et al.
Publicado: (2020)

Omeprazole- and Esomeprazole-associated Hypomagnesaemia: Data Mining of the Public Version of the FDA Adverse Event Reporting System
por: Tamura, Takao, et al.
Publicado: (2012)

A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system
por: Fang, Zhihong, et al.
Publicado: (2023)

Adverse Event Profiles of Platinum Agents: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations
por: Sakaeda, Toshiyuki, et al.
Publicado: (2011)

Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system
por: Xiao, Yao, et al.
Publicado: (2023)

Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS)
por: Zhang, Lin, et al.
Publicado: (2023)

Mining reported adverse events induced by potential opioid-drug interactions
por: Chen, Jinzhao, et al.
Publicado: (2020)

Adverse Event Profiles of 5-Fluorouracil and Capecitabine: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations
por: Kadoyama, Kaori, et al.
Publicado: (2011)

Mining FDA drug labels using an unsupervised learning technique - topic modeling
por: Bisgin, Halil, et al.
Publicado: (2011)

Hypersensitivity reactions to anticancer agents: Data mining of the public version of the FDA adverse event reporting system, AERS
por: Kadoyama, Kaori, et al.
Publicado: (2011)

An Early Adverse Drug Event Detection Approach with False Discovery Rate Control
por: Shi, Yi, et al.
Publicado: (2023)

Antifungal Drugs and Drug-Induced Liver Injury: A Real-World Study Leveraging the FDA Adverse Event Reporting System Database
por: Zhou, Zhi-Xuan, et al.
Publicado: (2022)

A Survey of the FDA's AERS Database Regarding Muscle and Tendon Adverse Events Linked to the Statin Drug Class
por: Hoffman, Keith B., et al.
Publicado: (2012)

Pediatric Drug Safety Surveillance in FDA-AERS: A Description of Adverse Events from GRiP Project
por: de Bie, Sandra, et al.
Publicado: (2015)

OpenVigil FDA – Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications
por: Böhm, Ruwen, et al.
Publicado: (2016)

Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
por: Li, Dongxuan, et al.
Publicado: (2023)

Big Data Mining and Adverse Event Pattern Analysis in Clinical Drug Trials
por: Federer, Callie, et al.
Publicado: (2016)

Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
por: Wu, Leihong, et al.
Publicado: (2019)

Platinum Agent-Induced Hypersensitivity Reactions: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS
por: Sakaeda, Toshiyuki, et al.
Publicado: (2011)

Aspirin- and Clopidogrel-associated Bleeding Complications: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS
por: Tamura, Takao, et al.
Publicado: (2012)

Mining comorbidities of opioid use disorder from FDA adverse event reporting system and patient electronic health records
por: Pan, Yiheng, et al.
Publicado: (2022)

A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System
por: Shu, Yamin, et al.
Publicado: (2022)

Systematic analysis of safety profile for darunavir and its boosted agents using data mining in the FDA Adverse Event Reporting System database
por: Tian, Xiaojiang, et al.
Publicado: (2021)

Assessing taxane-associated adverse events using the FDA adverse event reporting system database
por: Lao, Dong-Hui, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n51udihes13k5bg1lvca07581g